✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
Key takeaways
- High-intensity statins (rosuvastatin 20–40 mg, atorvastatin 40–80 mg) are first-line for established atherosclerotic disease and high-risk primary prevention.
- Moderate-intensity statins (atorvastatin 10–20 mg, simvastatin 20–40 mg, pitavastatin) suit lower-risk primary prevention or patients with statin-intolerance to high-intensity dosing.
- Ezetimibe adds ~15–25% extra LDL reduction and was validated by IMPROVE-IT for outcome benefit when stacked on a statin.
- Fibrates (fenofibrate) target triglycerides and HDL, not LDL — useful for mixed dyslipidaemia or severe hypertriglyceridaemia.
- Below: 10 best cholesterol medications across all major classes, with mechanism, indication match, and decision shortcut.
Best Cholesterol Medications in 2026: 10 Evidence-Backed Lipid-Lowering Drugs
Cholesterol-lowering treatment is statin-led but no longer statin-only. The 2024 ESC dyslipidaemia guidelines and 2024 ACC/AHA updates both move toward more aggressive LDL targets in established atherosclerotic disease (LDL <55 mg/dL) and routine combination therapy when monotherapy doesn’t reach target. This guide ranks the 10 most-used cholesterol medications, organised by drug class so you can match treatment to lipid profile and risk tier.
How modern lipid management is structured
Statins block HMG-CoA reductase — the rate-limiting enzyme of hepatic cholesterol synthesis. The downstream effect is upregulated LDL receptor density, which clears circulating LDL. Statins differ in potency: rosuvastatin and atorvastatin are most potent (high-intensity); simvastatin and pravastatin are moderate; pitavastatin is moderate-to-high with a metabolic-neutral profile.
Where statins alone don’t reach target, ezetimibe is added — it blocks intestinal cholesterol absorption and gives an additional 15–25% LDL drop. The IMPROVE-IT trial (2015) was the first non-statin LDL-lowering drug to show outcome benefit on top of a statin. PCSK9 inhibitors and bempedoic acid are newer add-ons but not stocked here. For triglyceride-driven dyslipidaemia (TG >500 mg/dL) or mixed dyslipidaemia, fenofibrate is the reference fibrate.
1. Atorvatin (Atorvastatin 5/10/20/40 mg)
Class: Statin (HMG-CoA reductase inhibitor) · Manufacturer: WHO-GMP certified · View product
Atorvastatin is the most-prescribed statin worldwide and the centerpiece of the LIPITOR-derived evidence base. The full dose range supports both primary prevention (10–20 mg, ~37–43% LDL reduction) and high-intensity therapy (40–80 mg, ~50–55% LDL reduction). The 5 mg starting dose is below trial-validated minimums; useful only for confirmed statin-intolerance situations where any dose is better than none.
Side effects: myalgia (~5–10% on dose-finding studies, much lower in blinded re-challenge — the SAMSON and StatinWISE trials demonstrated most “statin myalgia” is nocebo); rare myopathy; transient transaminitis (LFTs at 6 weeks then annually); slight increase in incident T2DM at high-intensity doses (offset by CV benefit).
Pick for: primary prevention with elevated 10-year CV risk, high-intensity therapy after MI or stroke, post-revascularisation lipid management.
2. Lipvas (Atorvastatin 10/20/40 mg)
Class: Statin · Manufacturer: Cipla · View product
Lipvas is Cipla’s atorvastatin brand — same molecule as Atorvatin, alternative manufacturer for those with brand preference. Therapeutically equivalent at all dose strengths. Useful when sourcing continuity matters across multi-month therapy.
Pick for: long-term atorvastatin therapy when alternative manufacturer is preferred.
3. Crestor (Rosuvastatin 5/10/20/40 mg)
Class: Statin · Manufacturer: AstraZeneca · View product
Rosuvastatin is the most potent statin per milligram — a 5 mg dose gives roughly the same LDL reduction as atorvastatin 10 mg. JUPITER trial (2008) established primary-prevention benefit in patients with elevated hsCRP and average LDL. STELLAR head-to-head trial showed superiority at equivalent milligram doses against atorva, simva, and prava. Hepatically excreted via CYP2C9 (less drug-interaction prone than CYP3A4 statins).
Pick for: high-intensity LDL lowering, statin patients on multiple CYP3A4-metabolised drugs, primary prevention with elevated hsCRP.
4. Rosuline (Rosuvastatin 5/10 mg)
Class: Statin · Manufacturer: Torrent · View product
Rosuline is Torrent’s rosuvastatin — same molecule, alternative budget-tier manufacturer. The 5 mg starting dose with up-titration to 10 mg covers most low-to-moderate intensity primary prevention cases. For high-intensity therapy (20–40 mg), Crestor or Rozucor at the higher strengths.
Pick for: low-to-moderate intensity rosuvastatin therapy, cost-conscious continuous treatment.
5. Rozucor (Rosuvastatin 10/20 mg)
Class: Statin · Manufacturer: Torrent · View product
Rozucor is Torrent’s mid-dose rosuvastatin range. The 10–20 mg window is what most secondary-prevention patients sit at after up-titration. Same evidence base as Crestor — choice between brands is preference and cost-driven.
Pick for: moderate-to-high intensity rosuvastatin therapy, secondary prevention after MI or stroke.
6. Pivasta (Pitavastatin 1/2/4 mg)
Class: Statin · Manufacturer: Torrent · View product
Pitavastatin is the newest statin in routine use, with two distinguishing features: minimal CYP450 metabolism (negligible drug interactions) and a metabolic-neutral profile (no detectable T2DM signal in REAL-CAD and J-PREDICT). Pitavastatin 2 mg is roughly equivalent to atorvastatin 10 mg or rosuvastatin 5 mg in LDL reduction. The 4 mg dose is the maximum.
Pick for: patients with HIV on antiretroviral therapy (where CYP-metabolised statins interact); patients with prediabetes or metabolic syndrome where T2DM-signal avoidance matters; statin-intolerant patients trying a different molecule.
7. Simvotin (Simvastatin 10/20/40 mg)
Class: Statin · Manufacturer: Cipla · View product
Simvastatin is the original statin with the longest evidence base (4S, HPS, A-Z). Moderate-intensity at 20–40 mg. Hepatically metabolised via CYP3A4 — many drug interactions (avoid with strong CYP3A4 inhibitors like clarithromycin, itraconazole, ritonavir; reduce dose with diltiazem and verapamil). The 80 mg dose is no longer recommended due to myopathy signal. Most patients on simvastatin who need higher LDL reduction should switch to atorvastatin or rosuvastatin rather than dose-escalating.
Pick for: stable long-term moderate-intensity therapy, simple lipid profiles where high-intensity isn’t needed.
8. Ezedoc (Ezetimibe 10 mg)
Class: Cholesterol absorption inhibitor · Manufacturer: Lupin · View product
Ezetimibe blocks the NPC1L1 transporter on intestinal enterocytes, reducing cholesterol absorption by ~50% and lowering LDL by ~15–25% as monotherapy. The IMPROVE-IT trial (2015) added ezetimibe to simvastatin in post-ACS patients and demonstrated cardiovascular event reduction beyond statin monotherapy — the first non-statin LDL-lowering drug to do so. Standard dose is 10 mg once daily; no dose-finding flexibility. Can be added when statin alone doesn’t reach LDL target, or used as monotherapy in confirmed statin-intolerance.
Pick for: add-on when statin alone doesn’t reach target LDL, statin-intolerant patients, post-ACS combination therapy.
9. Lipicard (Fenofibrate 145/160/200 mg)
Class: Fibrate (PPAR-α activator) · Manufacturer: USV · View product
Fenofibrate is the reference fibrate — a PPAR-α agonist that lowers triglycerides ~30–50% and raises HDL ~10–15%, with modest LDL effect. Primary indication is severe hypertriglyceridaemia (TG >500 mg/dL, where pancreatitis risk is real) and mixed dyslipidaemia. The FIELD trial showed cardiovascular benefit specifically in subgroups with mixed dyslipidaemia, but no overall mortality benefit when added to statin therapy in the broader ACCORD-Lipid analysis. PPAR-α activation also has small renal protective signal in T2DM.
Side effects: myopathy risk (especially in combination with statins — use cautiously), reversible creatinine bump (a marker of mild renal effect, not toxicity), gallstones in long-term use, transient transaminitis.
Pick for: severe hypertriglyceridaemia, mixed dyslipidaemia where statin alone doesn’t address TG, T2DM with mixed dyslipidaemia.
10. Choltran Sachet (Cholestyramine 4 g)
Class: Bile acid sequestrant · Manufacturer: Sun Pharma · View product
Cholestyramine binds bile acids in the intestine, preventing reabsorption and forcing the liver to use circulating cholesterol to synthesise replacements. LDL reduction ~15–30%. The original lipid-lowering drug class (LRC-CPPT trial, 1984) — bile-acid sequestrants were the first LDL-lowering drugs proven to reduce CV events. Modern role: secondary indication for cholestatic pruritus (bile-salt-driven itch in primary biliary cholangitis) and bile-acid diarrhoea. Less common as primary lipid drug because of GI tolerability and drug-interaction issues (binds many other oral medications).
Side effects: constipation, bloating, nausea early on; raised triglycerides (avoid if TG already >300); reduced absorption of fat-soluble vitamins (ADEK) on long-term use; binds and reduces absorption of many oral drugs (warfarin, levothyroxine, digoxin, statins) — separate dosing by 4 hours.
Pick for: cholestatic pruritus (primary indication today), bile-acid diarrhoea, statin-intolerant patient who can’t tolerate ezetimibe either, lipid management in pregnancy (the only LDL-lowering drug widely considered safe — fibrates and statins both contraindicated).
Comparison table: 10 cholesterol medications at a glance
| Treatment | Class | LDL reduction | Best for | Key consideration |
|---|---|---|---|---|
| Atorvatin | Statin | −37 to −55% | Primary & high-intensity | Most evidence; CYP3A4 |
| Lipvas | Statin | −37 to −55% | Atorva alt manufacturer | Cipla brand |
| Crestor | Statin | −45 to −60% | Highest-potency statin | CYP2C9; fewer DIs |
| Rosuline | Statin | −40 to −50% | Low-mod rosuva therapy | 5–10 mg only |
| Rozucor | Statin | −45 to −55% | Mod-high rosuva therapy | 10–20 mg range |
| Pivasta | Statin | −35 to −45% | CYP-neutral; metabolic-safe | No T2DM signal |
| Simvotin | Statin | −27 to −41% | Stable mod-intensity | Many CYP3A4 DIs |
| Ezedoc | NPC1L1 inhibitor | −15 to −25% | Stack on statin | IMPROVE-IT validated |
| Lipicard | Fibrate | Modest (TG-focused) | Mixed dyslipidaemia | −30 to −50% TG |
| Choltran | Bile-acid sequestrant | −15 to −30% | Pruritus, pregnancy | Many drug bindings |
Decision shortcut
- Primary prevention, moderate CV risk: Atorvatin 20 mg or Lipvas 20 mg. Up-titrate at 6–8 weeks if LDL not at target.
- Established CHD or post-MI: Crestor 20–40 mg or Atorvatin 40–80 mg (high-intensity). Add Ezedoc 10 mg if LDL stays above 55–70 mg/dL on max-tolerated statin.
- Statin myalgia on first attempt: blinded re-challenge first (most “statin intolerance” is nocebo per SAMSON). If real, switch to Pivasta 2 mg or Rosuline 5 mg.
- HIV on antiretrovirals: Pivasta or Crestor (rosuvastatin) — minimal CYP3A4 metabolism avoids interactions with protease inhibitors and ritonavir-boosted regimens.
- Mixed dyslipidaemia (high LDL + high TG): statin first, add Lipicard if TG >200 after statin.
- Severe hypertriglyceridaemia (TG >500): Lipicard alone first to reduce pancreatitis risk; add statin once TG <500.
- Cholestatic pruritus (PBC): Choltran Sachet 4 g once or twice daily — primary first-line for the itch.
- Pregnancy or planning conception: stop statins and fibrates; Choltran is the only widely-considered-safe lipid drug if treatment is essential.
Frequently asked questions
What is the best cholesterol medication?
For most patients, a statin — atorvastatin or rosuvastatin. The 2024 ESC and ACC/AHA guidelines recommend high-intensity statin (rosuva 20–40 mg or atorva 40–80 mg) for established atherosclerotic disease and high-risk primary prevention. The “best” is the one you’ll actually take consistently; tolerability and adherence matter more than tiny potency differences between molecules.
Is rosuvastatin or atorvastatin more effective?
Per milligram, rosuvastatin is more potent — STELLAR head-to-head showed rosuva 5 mg roughly equals atorva 10 mg, rosuva 10 mg roughly equals atorva 20 mg. At maximum doses (rosuva 40 mg vs atorva 80 mg), rosuva is about 5–7% better on LDL reduction. Both have strong CV outcome evidence; choice often comes down to drug interactions and patient-specific factors.
Are statins safe?
Yes — large-scale meta-analyses show statins reduce cardiovascular mortality with a strongly favourable risk-benefit profile. Real adverse effects (myopathy, transaminitis) are uncommon. The widely-discussed “statin myalgia” is largely nocebo: SAMSON and StatinWISE blinded re-challenge trials demonstrated most patients reporting muscle symptoms had identical symptoms on placebo. The small T2DM signal at high-intensity doses is offset by larger CV benefit.
Should I combine a statin with ezetimibe?
Yes, when statin alone doesn’t reach LDL target. IMPROVE-IT trial (2015) confirmed CV event reduction with statin + ezetimibe vs statin alone in post-ACS patients. Standard sequence: max-tolerated statin first, then add ezetimibe 10 mg, then consider PCSK9 inhibitor or bempedoic acid if available.
What if I can’t tolerate any statin?
True statin intolerance is rare (most reported intolerance is nocebo per blinded trials). For genuine intolerance: try rotation through 2–3 different molecules at lower doses (Pivasta and Rosuline are common alternatives); intermittent dosing (alternate days, twice weekly); ezetimibe monotherapy (Ezedoc); add bile-acid sequestrant (Choltran). PCSK9 inhibitors and bempedoic acid are stronger alternatives but not stocked here.
Do I need a statin if my LDL is borderline?
Depends on absolute risk. Use a 10-year CV risk calculator (QRISK3, ASCVD, SCORE2). LDL 130–160 with low risk = lifestyle first. Same LDL with high risk (diabetes, hypertension, smoking, family history of premature CHD) = statin recommended even at borderline LDL. Risk drives the decision more than LDL number alone.
What about red yeast rice or other natural alternatives?
Red yeast rice contains monacolin K, which is chemically identical to lovastatin. Effectiveness is variable across products (no quality standardisation), and you may get an inconsistent or unsafely-high statin dose. Not a credible alternative to a quality-controlled prescription statin. Plant sterols (2 g/day) reduce LDL ~10% and are reasonable adjuncts; nothing matches statin magnitude.
Can I stop statins once my cholesterol is normal?
No — for most patients, cholesterol rebounds within weeks of stopping. The benefit is from continuous LDL receptor upregulation, not a one-time correction. Long-term continuous therapy is the model.
Bottom line
Modern lipid management is statin-led, intensity-graded by absolute CV risk, and increasingly combined with ezetimibe to reach aggressive LDL targets. Atorvastatin and rosuvastatin cover most patients; pitavastatin is the metabolic-safe alternative; ezetimibe is the validated non-statin add-on; fibrates target triglycerides specifically; cholestyramine survives for niche indications.
Related guides: Best BP medications 2026 · All cholesterol medication products · Heart & blood pressure category
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.